LivaNova (NASDAQ:LIVN) Director Sells $136,350.00 in Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares in the company, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

LivaNova Trading Up 1.0%

Shares of LIVN opened at $73.80 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $4.05 billion, a P/E ratio of 37.85 and a beta of 0.82. The stock’s fifty day simple moving average is $66.59 and its 200 day simple moving average is $64.28. LivaNova PLC has a twelve month low of $41.01 and a twelve month high of $75.82.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the company posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities research analysts forecast that LivaNova PLC will post 3.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on LIVN. Robert W. Baird cut their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Barclays increased their price target on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Piper Sandler reiterated an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a report on Thursday, February 19th. Finally, Needham & Company LLC increased their price target on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, LivaNova has an average rating of “Moderate Buy” and a consensus target price of $79.38.

Institutional Trading of LivaNova

Several large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC increased its holdings in LivaNova by 17.3% in the 4th quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock valued at $214,376,000 after purchasing an additional 514,268 shares in the last quarter. Artisan Partners Limited Partnership grew its stake in shares of LivaNova by 94.5% during the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after acquiring an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of LivaNova by 83.5% during the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after acquiring an additional 1,067,349 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of LivaNova by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock valued at $143,491,000 after acquiring an additional 34,812 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of LivaNova by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock valued at $132,606,000 after acquiring an additional 496,165 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.